# EDGAR Filing Document

**Accession Number:** 0001650664
**File Stem:** 0001558370-23-000130
**Filing Date:** 2023-1
**Character Count:** 5124
**Document Hash:** d41c858c85d6dc757ceb62c77ee1ba37
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-000130.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001558370-23-000130

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230107

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Editas Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001650664
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 464097528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37687
- **FILM NUMBER:** 23516762

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-401-9000

**MAIL ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

?xml version='1.0' encoding='UTF-8'?

**UNITED STATESSECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

### FORM 8-K
**CURRENT REPORTPursuant to Section 13 or 15(d)of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 7, 2023

### Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37687** | **46-4097528** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **11 Hurley StreetCambridge, Massachusetts** | **02141** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | EDIT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 7, 2023, Editas Medicine, Inc. (the "Company") and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023. Pursuant to the terms of an agreement (the "Separation Agreement") dated as of January 7, 2023, Dr. Shearman will receive (i) his base salary for a period of 12 months following the date of his separation (the "Severance Period"), (ii) company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act for the Severance Period, and (iii) the amount of any unpaid annual bonus determined by the Company's Board of Directors to be payable to him for the 2022 calendar year. All payments and benefits provided under the Separation Agreement are contingent upon the execution and effectiveness of, and Dr. Shearman's continued compliance with, a release of claims agreement between Dr. Shearman and the Company. The Separation Agreement also contains standard non-disparagement and confidentiality provisions.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **EDITAS MEDICINE, INC.** | **EDITAS MEDICINE, INC.** |
| Date: | January 9, 2023 | By: | /s/ Gilmore O'Neill |
|  |  |  | Gilmore O'Neill<br>President and Chief Executive Officer |

---